MedPath

Safe shortening of antibiotic treatment duration for complicated Staphylococcus aureus bacteremia

Conditions
Staphylococcus aureus bacteremia
Registration Number
NL-OMON28621
Lead Sponsor
Amsterdam UMC
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Pending
Sex
Not specified
Target Recruitment
400
Inclusion Criteria

Adults with methicillin-sensitive complicated SAB with satisfactory clinical response to initial treatment will be eligible for inclusion.

Exclusion Criteria

Patients with infected prosthetic material or pregnant/lactating will be excluded.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
The primary endpoint is a composite of all-cause mortality or bacteriologically confirmed disease relapse.
Secondary Outcome Measures
NameTimeMethod
Secondary outcomes will include antibiotic-related toxicity, length of hospital admission, perceived quality of life and societal costs.
© Copyright 2025. All Rights Reserved by MedPath